ToplineNovavax has started the phase 3 trial for its experimental coronavirus vaccine in the United Kingdom, where a surge of coronavirus infections should provide good conditions for the trial, making it the fifth vaccine candidate funded by the Trump administration’s Operation Warp Speed to enter late-stage testing. Key BackgroundNovavax, which has not yet brought a vaccine to market, received $1.6 billion from the U.S. federal government to fund development and mass production of its experimental coronavirus vaccine. That’s how much Novavax says it has secured in funding for its global coronavirus vaccine program, including up to $388 million in funding from the Coalition for Epidemic Preparedness Innovations. What To Watch ForIf the vaccine proves safe, Novavax said it currently has the ability to manufacture 2 billion doses by mid-2021. Further ReadingStatementCovid-19 Vaccine From Novavax Begins Phase 3 Trial in U.K. (Wall Street Journal)Novavax Stock Jumps 8.5% After ‘Positive’ Early Results For Its Coronavirus Vaccine (Forbes)Full coverage and live updates on the Coronavirus

Source: Forbes September 24, 2020 23:03 UTC